Scholarlink

<p>There is a need for inflammatory bowel disease (IBD) treatments with durable efficacy and safety, and sphingosine-1-phosphate (S1P) modulators are emerging as a promising therapeutic target in the field of IBD. Ozanimod and etrasimod are two S1P modulators that are approved for the management of ulcerative colitis and undergoing trials for Crohn’s disease. Additional S1P modulators are also being investigated.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Consider sphingosine-1-phosphate modulators alongside existing options when treating inflammatory bowel disease

  • 期刊论文

  • 发表日期：

    2025年10月31日

查看全文
  • Esther S. Kim,
  • Sheridan M. Hoy

摘要

There is a need for inflammatory bowel disease (IBD) treatments with durable efficacy and safety, and sphingosine-1-phosphate (S1P) modulators are emerging as a promising therapeutic target in the field of IBD. Ozanimod and etrasimod are two S1P modulators that are approved for the management of ulcerative colitis and undergoing trials for Crohn’s disease. Additional S1P modulators are also being investigated.